Breast cancer progression, prognosis and prospective outcomes

According to the work done in my lab the most significant issues is the average age at which the breast cancer effect the women of east and west, there is a clear difference of 10 years as the average age of eastern women is 50 years and western female gets at 60 years and this difference of 10 year is being carried by the migrant women in the west as well and many studies should this difference is purely genetic and not environmental. Based these studies and advocacy group the age of mammography has been reduced to 10 years for eastern origin women. Once the breast cancer has been diagnosed the next step is prognosis. Family history does play a different role in prognosis according to a contemporarily published study where an accumulated number of ER negative & PR negative breast cancer was acclaimed among younger Spanish women who have a family account of the disease [1]. The established/routinely used prognostic markers which are being used by some of the highly respected institutes are ER, PR, Her-2, p53, CD31, Ki-67/PCNA. Trastuzumab is being offered to Her-2 positive patients who will benefit with this monoclonal drug or in other words Her-2 is being performed on a selective group of patients. Whereas ER, PR, p53, CD31, Ki-67/PCNA are being performed on almost every breast cancer patient.